Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2009

01-04-2009 | Original Article

A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin

Authors: Kurt Van der Speeten, O. A. Stuart, H. Mahteme, P. H. Sugarbaker

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2009

Login to get access

Abstract

Purpose

A pharmacologic analysis of intracavitary doxorubicin in the treatment of patients with intracavitary cancer dissemination was performed to further evaluate the possible benefits of this treatment modality.

Methods

Twenty appendiceal malignancy patients with peritoneal carcinomatosis (PC), three appendiceal malignancy patients with direct extension into the pleural cavity, 20 patients with peritoneal mesothelioma and one patient with pleural mesothelioma were available for pharmacologic monitoring. After intraperitoneal or intrapleural administration of doxorubicin, plasma and peritoneal fluid samples were obtained at 15, 30, 45, 60 and 90 min in all patients. After intrapleural administration, plasma and pleural fluid samples were collected at similar intervals. Tumor and normal tissues were obtained when available. Doxorubicin concentrations were determined by high-performance liquid chromatography (HPLC).

Results

Intraperitoneal doxorubicin showed a prolonged retention in the peritoneal cavity. Doxorubicin concentrations in tumor tissue were consistently elevated above intraperitoneal concentrations from 30 through 90 min. For appendiceal malignancy, the concentrations of doxorubicin were significantly higher in minimally aggressive mucinous tumors. Pleural chemotherapy solutions retained doxorubicin to a greater extent than peritoneal fluid.

Conclusions

Doxorubicin shows characteristics favorable for intracavitary administration with sequestration of doxorubicin in cancer nodules.
Literature
1.
Zoetmulder FA (1982) Modelstudies over het colorectale carcinoom. Amsterdam, Rodopi
2.
Sugarbaker PH, Cunliffe WJ, Belliveau J et al (1989) Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 16(4):83–97PubMed
3.
4.
5.
Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335(6):1950–1955PubMedCrossRef
6.
Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Oncology Group. J Clin Oncol 19(4):1001–1007PubMed
7.
Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34–43PubMedCrossRef
8.
Verwaal VJ, Van Ruth S, De Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737–3743PubMedCrossRef
9.
Sugarbaker PH (2005) An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution. J Surg Oncol 92(2):142–146PubMedCrossRef
10.
Cummings J, Stuart JFB, Calman KC (1984) Determination of adriamycin, adriamycinol and their 7-deoxyaclycones in human serum by high-performance liquid chromatography. J Chromatogr 311:125–133PubMedCrossRef
11.
Ronnett BM, Zahn CM, Kurman RJ et al (1995) Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol 19(12):1390–1408PubMedCrossRef
12.
Cerruto CA, Brun EA, Chang D, Sugarbaker PH (2006) Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med 130(11):1654–1661PubMed
13.
14.
Hahn GM, Braun J, Har-Kedar I (1975) Thermochemotherapy: synergism between hyperthermia (42–43°) and adriamycin (or bleomycin) in mammalian cell inactivation. Proc Nat Acad Sci 72(3):937–940PubMedCrossRef
15.
Lane P, Vichi P, Bain DL et al (1987) Temperature dependence studies of adriamycin uptake and cytotoxocity. Cancer Res 42:4038–4042
16.
Carter SK (1981) Adriamycin—a review. J Natl Cancer Inst 55:1265–1274
17.
Johansen PB (1981) Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother Pharmacol 5:267–270PubMedCrossRef
18.
Ozols RF, Young RC, Speyer JL et al (1982) Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42:4265–4269PubMed
19.
Ozols RF, Grotzinger KR, Fisher RI et al (1979) Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer. Cancer Res 39:3202–3208PubMed
20.
Ozols RF, Locker GY, Doroshow JH et al (1979) Pharmacokinetics and tissue penetration in murine ovarian cancer. Cancer Res 39:3209–3214PubMed
21.
Ozols RF, Willson JKV, Weltz MD et al (1980) Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. Cancer Res 40:4109–4112PubMed
22.
Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D (2005) Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 10(2):112–122PubMedCrossRef
23.
Roboz J, Jacobs AJ, Holland JF et al (1981) Intraperitoneal infusion of doxorubicin in the treatment of gynecologic carcinomas. Med Pediatr Oncol 9:245–250PubMedCrossRef
24.
Yan TD, Welch L, Black D et al (2007) A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18(5):827–834PubMedCrossRef
25.
Raspagliesi F, Kusamura S, Campos Torres JC et al (2006) Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol 32(6):671–675PubMedCrossRef
26.
Yan TD, Black D, Savady R et al (2007) A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 14(2):484–492PubMedCrossRef
27.
Stelin G, Rippe B (1990) A phenomenological interpretation of the variation in dialysate volume with dwell time in CAPD. Kidney Int 38(3):465–472PubMedCrossRef
28.
Ceelen WP, Påhlman L, Mahteme H (2006) Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. In Peritoneal carcinomatosis: a multidisciplinary approach. Cancer Treat Res, Springer, 195–214
29.
Dedrick RL, Flessner MF (1997) Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89(7):480–487PubMedCrossRef
30.
Sugarbaker PH, Stuart OA (2007) Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan. Cancer Chemother Pharmacol 59(2):151–155PubMedCrossRef
Metadata
Title
A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin
Authors
Kurt Van der Speeten
O. A. Stuart
H. Mahteme
P. H. Sugarbaker
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0800-0

Other articles of this Issue 5/2009

Cancer Chemotherapy and Pharmacology 5/2009 Go to the issue

Short Communication

Intracellular disposition of fludarabine triphosphate in human natural killer cells

Original Article

A multiple-center phase II study of biweekly oxaliplatin and tegafur–uracil/leucovorin for chemonaive patients with advanced gastric cancer

Original Article

Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature

Clinical Trial Report

Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial

Original Article

Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer

Original Article

Dependence on PI3K/Akt signaling for malignant rhabdoid tumor cell survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits